JP2016513133A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513133A5
JP2016513133A5 JP2015559595A JP2015559595A JP2016513133A5 JP 2016513133 A5 JP2016513133 A5 JP 2016513133A5 JP 2015559595 A JP2015559595 A JP 2015559595A JP 2015559595 A JP2015559595 A JP 2015559595A JP 2016513133 A5 JP2016513133 A5 JP 2016513133A5
Authority
JP
Japan
Prior art keywords
composition
donepezil
release
administered
sustained
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015559595A
Other languages
English (en)
Japanese (ja)
Other versions
JP6429808B2 (ja
JP2016513133A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/059302 external-priority patent/WO2014132218A1/en
Publication of JP2016513133A publication Critical patent/JP2016513133A/ja
Publication of JP2016513133A5 publication Critical patent/JP2016513133A5/ja
Application granted granted Critical
Publication of JP6429808B2 publication Critical patent/JP6429808B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015559595A 2013-02-28 2014-02-27 特異的なインビトロ溶出プロファイルまたは薬物動態パラメーターを有するドネペジル医薬組成物 Expired - Fee Related JP6429808B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN991/KOL/2012 2013-02-28
IN991KO2012 2013-02-28
PCT/IB2014/059302 WO2014132218A1 (en) 2013-02-28 2014-02-27 Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters

Publications (3)

Publication Number Publication Date
JP2016513133A JP2016513133A (ja) 2016-05-12
JP2016513133A5 true JP2016513133A5 (enExample) 2017-03-30
JP6429808B2 JP6429808B2 (ja) 2018-11-28

Family

ID=50288205

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015559595A Expired - Fee Related JP6429808B2 (ja) 2013-02-28 2014-02-27 特異的なインビトロ溶出プロファイルまたは薬物動態パラメーターを有するドネペジル医薬組成物

Country Status (11)

Country Link
US (1) US20160015698A1 (enExample)
EP (1) EP2961393B1 (enExample)
JP (1) JP6429808B2 (enExample)
KR (1) KR102241113B1 (enExample)
CN (1) CN105163723A (enExample)
BR (1) BR112015020771A2 (enExample)
ES (1) ES2842208T3 (enExample)
MX (1) MX378413B (enExample)
RU (1) RU2015140567A (enExample)
WO (1) WO2014132218A1 (enExample)
ZA (1) ZA201506665B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102142026B1 (ko) * 2017-05-31 2020-08-06 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1133230A4 (en) * 1998-11-23 2004-05-26 Bonnie M Davis DOSAGE FORMULAS FOR ACETYLCHOLINESTERASE INHIBITORS
EP1368000A4 (en) * 2001-03-13 2004-12-01 Penwest Pharmaceuticals Co CHRONOTHERAPEUTIC PHARMACEUTICAL FORMS CONTAINING A GLUCOCORTICOSTEROID
AR040680A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida
US20050232990A1 (en) 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
US20060280789A1 (en) 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
CN101090738A (zh) * 2004-12-27 2007-12-19 卫材R&D管理有限公司 含有碱性药物或其盐的基质型缓释制剂及其制备方法
US20060159753A1 (en) 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20070129402A1 (en) 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
KR100866720B1 (ko) 2004-12-27 2008-11-05 에자이 알앤드디 매니지먼트 가부시키가이샤 항치매 약물의 안정화 방법
NZ556630A (en) * 2005-01-27 2010-12-24 Alembic Ltd Extended release formulation of levetiracetam including a hydrophilic rate controlling polymer
BRPI0607017B8 (pt) * 2005-04-06 2021-05-25 Adamas Pharmaceuticals Inc composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
US20130059003A1 (en) 2009-12-04 2013-03-07 Dr. Reddy's Laboratories, Inc. Sustained release donepezil formulations
US20110218216A1 (en) 2010-01-29 2011-09-08 Kumaravel Vivek Extended release pharmaceutical composition of donepezil
EP2366378A1 (en) * 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
CN102309465B (zh) * 2010-06-30 2015-04-22 天津药物研究院 含盐酸多奈哌齐活性成分的缓释片及其制备方法和用途
WO2012035409A1 (en) * 2010-09-14 2012-03-22 Rubicon Research Private Limited Sustained release compositions of anti-alzheimer's agents

Similar Documents

Publication Publication Date Title
JP2019048843A5 (enExample)
JP2008520736A5 (enExample)
JP2020514318A5 (enExample)
JP2016540738A5 (enExample)
JP2015523407A5 (enExample)
JP2015504871A5 (enExample)
WO2017141104A8 (en) Method for inducing a sustained immune response
JP2015038135A5 (enExample)
JP2014515373A5 (enExample)
JP2017528457A5 (enExample)
JP2013531041A5 (enExample)
JP2018537513A5 (enExample)
JP2020516646A5 (enExample)
WO2015087258A8 (en) Modified-release therapeutic systems for oral administration of menthol in the treatment of intestinal disorders
JP2005528430A5 (enExample)
JP2021509395A5 (enExample)
JP2020500864A5 (enExample)
JP2020511419A5 (enExample)
JP2015531749A5 (enExample)
JP2019507786A5 (enExample)
JP2016505050A5 (enExample)
EP4410295A3 (en) Use of vibegron to treat overactive bladder
JP2015504094A5 (enExample)
WO2020128816A3 (en) Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
JP2013523628A5 (enExample)